Evidence map›Paper›PMID 40953287›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Switchbody, an Antigen-Responsive Enzyme Switch Based on Antibody and Its Working Principle.

Takanobu Yasuda, Yoshiyuki Ueno, Masahiko Taguchi, Naoya Tochio, Hiromasa Yagi, Shuma Yazaki, Ryoichi Arai, Bo Zhu, Takanori Kigawa, Hiroshi Ueda and 1 more

Abstract read
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Switchbody, an Antigen-Responsive Enzyme Switch Based on Antibody and Its Working Principle.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Takanobu YasudaLaboratory for Chemistry and Life Science, Institute of Integrated Research, Institute of Science Tokyo, Yokohama, 226-8501, Japan.
Yoshiyuki UenoGraduate School of Life Science and Technology, Institute of Science Tokyo, Yokohama, 226-8501, Japan.
Masahiko TaguchiInstitute of Multidisciplinary Research for Advanced Materials, Tohoku University, Sendai, 980-8577, Japan.
Naoya TochioLaboratory for Cellular Structural Biology, Center for Biosystems Dynamics Research, RIKEN, Yokohama, 230-0045, Japan.
Hiromasa YagiLaboratory for Cellular Structural Biology, Center for Biosystems Dynamics Research, RIKEN, Yokohama, 230-0045, Japan.
Shuma YazakiDepartment of Applied Biology, Faculty of Textile Science and Technology, Shinshu University, Ueda, 386-8567, Japan.
Ryoichi AraiDepartment of Applied Biology, Faculty of Textile Science and Technology, Shinshu University, Ueda, 386-8567, Japan.
Bo ZhuLaboratory for Chemistry and Life Science, Institute of Integrated Research, Institute of Science Tokyo, Yokohama, 226-8501, Japan.
Takanori KigawaLaboratory for Cellular Structural Biology, Center for Biosystems Dynamics Research, RIKEN, Yokohama, 230-0045, Japan.
Hiroshi UedaLaboratory for Chemistry and Life Science, Institute of Integrated Research, Institute of Science Tokyo, Yokohama, 226-8501, Japan.
Tetsuya KitaguchiLaboratory for Chemistry and Life Science, Institute of Integrated Research, Institute of Science Tokyo, Yokohama, 226-8501, Japan.ORCID https://orcid.org/0000-0001-6701-1933

Funding

Cooperative Research Program of "Network Joint Research Center for Materials and Devices" (MEXT)"Crossover Alliance to Create the Future with People, Intelligence, and Materials" (MEXT) JP2024Y008Japan Science Society 2024-3031JSPS KAKENHI JP18H03851JSPS KAKENHI JP19H02522JSPS KAKENHI JP23K13607JSPS KAKENHI JP24K01264
6 · The paper itself

Abstract

An enzyme switch, termed "Switchbody", is developed by fusing an antibody with a fragment of a split enzyme for the precise regulation of enzyme activity in response to an antigen. A luciferase-based Switchbody is engineered by fusing the NanoLuc luciferase fragment HiBiT to the N-terminus of an antibody. The enzyme activity of the Switchbody increases upon the addition of an antigen in a dose-dependent manner in the presence of the complementary fragment LgBiT and its substrate furimazine, demonstrating the potential of the luciferase-based Switchbody as a biosensor. As its working principle, ELISA shows that the interaction between HiBiT and LgBiT is facilitated by antigen binding. Moreover, X-ray crystallography and NMR reveal the heterogeneous trapped state of the HiBiT region and an increasing motility of HiBiT region upon antigen binding, respectively. MD simulations and luminescence measurements show that antigen disrupted the trapping of HiBiT in the antibody, enabling its release. By applying this "Trap and Release" principle to Protein M, an antibody-binding protein, label-free IgG antibodies are successfully converted into bioluminescent Switchbodies. This adaptable Switchbody platform has the potential to expand switching technology beyond luciferase to various other enzymes in the future.

Indexed as

AntibodiesAntigensBiosensing TechniquesLuciferasesCrystallography, X-RayHumansAntibodiesAntigensLuciferasesantibodiesenzyme switchimmunosensorsmolecular dynamicsprotein structures

Identifiers

PMID40953287
PMCPMC12667551

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.